Okada Naoya, Narita Yoshiaki, Nanno Yoshihide, Shimaguchi Mayu, Imamura Kiyotaka, Inoue Rei, Nakamura Toru, Takada Minoru, Kato Hiroaki, Suzuki On, Ambo Yoshiyasu, Nakamura Fumitaka, Kishida Akihiro, Kashimura Nobuichi, Matsunami Osamu
Dept. of Surgery, Teine Keijinkai Hospital.
Gan To Kagaku Ryoho. 2012 Sep;39(9):1399-402.
We report the long-term survival of a patient with metastatic breast cancer treated with trastuzumab and chemoendocrine therapy. The patient was a 60-year-old female. She underwent right mastectomy with axillary lymphadenectomy I c for advanced right breast cancer in 1999. In 2007, she consulted our hospital for treatment of recurrent giant liver metastasis. A giant liver metastasis up to 15 cm in diameter was detected by CT upon arrival. After 4 years of trastuzumab and chemoendocrine therapy, she was diagnosed as in progressive remission with good quality of life. Breast cancer with liver metastasis often can be life-threatening. Therefore, an optimal chemotherapy should be applied as soon as possible. Trastuzumab and chemoendocrine therapy showed efficacy for the treatment of a HER2-positive breast cancer with recurrent giant liver metastasis.
我们报告了一名接受曲妥珠单抗和化疗内分泌治疗的转移性乳腺癌患者的长期生存情况。该患者为60岁女性。1999年,她因晚期右乳腺癌接受了右乳房切除术及腋窝淋巴结I c清扫术。2007年,她因复发性巨大肝转移到我院就诊。入院时CT检查发现直径达15 cm的巨大肝转移灶。经过4年的曲妥珠单抗和化疗内分泌治疗,她被诊断为病情逐渐缓解,生活质量良好。伴有肝转移的乳腺癌通常可能危及生命。因此,应尽快应用最佳化疗方案。曲妥珠单抗和化疗内分泌治疗对治疗HER2阳性且伴有复发性巨大肝转移的乳腺癌显示出疗效。